Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 6:9:25-33.
doi: 10.2147/RRTM.S125204. eCollection 2018.

Elimination of lymphatic filariasis: current perspectives on mass drug administration

John O Gyapong  1 , Irene O Owusu  2 , Frances B da-Costa Vroom  3 , Ernest O Mensah  4 , Margaret Gyapong  5
Affiliations
Review

Elimination of lymphatic filariasis: current perspectives on mass drug administration

John O Gyapong et al. Res Rep Trop Med. .

Abstract

Following the London declaration on neglected tropical diseases (NTDs) in 2012 and inspired by the WHO 2020 roadmap to control or eliminate NTDs, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) intensified preventive chemotherapy and management of morbidity as the two main strategies to enhance progress towards the elimination of lymphatic filariasis (LF). This paper focuses on current perspectives of mass drug administration (MDA) towards the elimination of LF. The goal of MDA is to reduce the density of parasites circulating in the blood of infected persons and the intensity of infection in communities to levels where transmission is no longer sustainable by the mosquito vector. Three drugs, diethylcarbamazine, albendazole, and ivermectin are currently available for LF treatment, and their effectiveness and relative safety have opened the possibility of treating the entire population at risk. Currently, almost all LF endemic countries rely on the single-dose two-drug regimen recommended by the GPELF to achieve elimination. The 4th WHO report on NTDs has indicated that considerable progress has been made towards elimination of LF in some countries while acknowledging some challenges. In this review, we conclude that the 2020 elimination goal can be achieved if issues pertaining to the drug distribution, health system and implementation challenges are addressed.

Keywords: community health worker; disease elimination; lymphatic filariasis; mass drug administration; neglected tropical diseases; treatment compliance.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
MDA activity cycle. Abbreviation: MDA, mass drug administration.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention Recommendations of the International Task Force for Disease Eradication. Morb Mortal Wkly Rep. 1993;42(RR-16):1–27. - PubMed
    1. Ichimori K, King JD, Engels D, et al. Global Programme to Eliminate Lymphatic Filariasis: the processes underlying programme success. PLoS Negl Trop Dis. 2014;8(12):e 3328. - PMC - PubMed
    1. World Health Organization . Progress report 2000–2009 and strategic plan 2010–2020 of the global programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic filariasis. Geneva: WHO; 2010. [Accessed January 5, 2016]. Available from: http://www.who.int/iris/handle/10665/44473.
    1. Boyd A, Won KY, McClintock SK, et al. A community-based study of factors associated with continuing transmission of lymphatic filariasis in Leogane, Haiti. PLoS Negl Trop Dis. 2010;4(3):1–10. - PMC - PubMed
    1. Karam M, Ottesen E. The control of lymphatic filariasis. Med Trop (Mars) 2000;60(3):291–296. French. - PubMed

LinkOut - more resources